CA2092323A1 - Targeting viruses and cells for selective internalization by cells - Google Patents
Targeting viruses and cells for selective internalization by cellsInfo
- Publication number
- CA2092323A1 CA2092323A1 CA 2092323 CA2092323A CA2092323A1 CA 2092323 A1 CA2092323 A1 CA 2092323A1 CA 2092323 CA2092323 CA 2092323 CA 2092323 A CA2092323 A CA 2092323A CA 2092323 A1 CA2092323 A1 CA 2092323A1
- Authority
- CA
- Canada
- Prior art keywords
- virus
- cell
- modified
- receptor
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 181
- 230000008685 targeting Effects 0.000 title claims description 10
- 238000000034 method Methods 0.000 claims abstract description 55
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 13
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 13
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 13
- 238000001727 in vivo Methods 0.000 claims abstract description 8
- 239000013598 vector Substances 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 203
- 102000005962 receptors Human genes 0.000 claims description 56
- 108020003175 receptors Proteins 0.000 claims description 56
- 102000005427 Asialoglycoprotein Receptor Human genes 0.000 claims description 32
- 108010006523 asialoglycoprotein receptor Proteins 0.000 claims description 32
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- 210000000605 viral structure Anatomy 0.000 claims description 19
- 239000003446 ligand Substances 0.000 claims description 17
- 230000001413 cellular effect Effects 0.000 claims description 16
- 208000006454 hepatitis Diseases 0.000 claims description 14
- 231100000283 hepatitis Toxicity 0.000 claims description 14
- 210000003494 hepatocyte Anatomy 0.000 claims description 10
- 150000001720 carbohydrates Chemical group 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 7
- 244000052637 human pathogen Species 0.000 claims description 7
- 239000008101 lactose Substances 0.000 claims description 7
- 241001430294 unidentified retrovirus Species 0.000 claims description 7
- 235000014633 carbohydrates Nutrition 0.000 claims description 6
- 229930182830 galactose Natural products 0.000 claims description 6
- 230000012202 endocytosis Effects 0.000 claims description 5
- 239000013603 viral vector Substances 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 210000005260 human cell Anatomy 0.000 claims description 4
- 230000010076 replication Effects 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 238000012412 chemical coupling Methods 0.000 claims description 3
- 230000002950 deficient Effects 0.000 claims description 3
- 230000001524 infective effect Effects 0.000 claims description 3
- 230000001717 pathogenic effect Effects 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 244000052769 pathogen Species 0.000 claims description 2
- 210000004102 animal cell Anatomy 0.000 claims 8
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 3
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000010415 tropism Effects 0.000 abstract description 4
- 239000012678 infectious agent Substances 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 35
- 241000700721 Hepatitis B virus Species 0.000 description 20
- 108010084541 asialoorosomucoid Proteins 0.000 description 19
- 239000002609 medium Substances 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 13
- 230000003612 virological effect Effects 0.000 description 13
- 241000283984 Rodentia Species 0.000 description 10
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 9
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 9
- 108010002913 Asialoglycoproteins Proteins 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 108090001008 Avidin Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 108020000999 Viral RNA Proteins 0.000 description 5
- 238000007385 chemical modification Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 108010067390 Viral Proteins Proteins 0.000 description 4
- 102000005936 beta-Galactosidase Human genes 0.000 description 4
- 108010005774 beta-Galactosidase Proteins 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000004779 membrane envelope Anatomy 0.000 description 3
- 239000007758 minimum essential medium Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 239000003656 tris buffered saline Substances 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108010061952 Orosomucoid Proteins 0.000 description 2
- 102000012404 Orosomucoid Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 230000005149 ecotropism Effects 0.000 description 2
- 230000001159 endocytotic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000001744 histochemical effect Effects 0.000 description 2
- -1 iminomethoxyethyl Chemical class 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- UVGHPGOONBRLCX-NJSLBKSFSA-N (2,5-dioxopyrrolidin-1-yl) 6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O UVGHPGOONBRLCX-NJSLBKSFSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- KUWPCJHYPSUOFW-YBXAARCKSA-N 2-nitrophenyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1[N+]([O-])=O KUWPCJHYPSUOFW-YBXAARCKSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 101710125089 Bindin Proteins 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 101100279860 Caenorhabditis elegans epg-2 gene Proteins 0.000 description 1
- 102100035605 Cas scaffolding protein family member 4 Human genes 0.000 description 1
- 241000237074 Centris Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241001635598 Enicostema Species 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 101000947106 Homo sapiens Cas scaffolding protein family member 4 Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027626 Milia Diseases 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 101100156763 Schizosaccharomyces pombe (strain 972 / ATCC 24843) wos2 gene Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102000007238 Transferrin Receptors Human genes 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- CUJRVFIICFDLGR-UHFFFAOYSA-N acetylacetonate Chemical compound CC(=O)[CH-]C(C)=O CUJRVFIICFDLGR-UHFFFAOYSA-N 0.000 description 1
- 101150115889 al gene Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 108010044715 asialofetuin Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 241000902900 cellular organisms Species 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000000276 potassium ferrocyanide Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- XOGGUFAVLNCTRS-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] XOGGUFAVLNCTRS-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/10—Vectors comprising a non-peptidic targeting moiety
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59095690A | 1990-10-01 | 1990-10-01 | |
| US590,956 | 1990-10-01 | ||
| US72270091A | 1991-06-28 | 1991-06-28 | |
| US722,700 | 1991-06-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2092323A1 true CA2092323A1 (en) | 1992-04-02 |
Family
ID=27081003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2092323 Abandoned CA2092323A1 (en) | 1990-10-01 | 1991-09-27 | Targeting viruses and cells for selective internalization by cells |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0553235A1 (enExample) |
| JP (1) | JPH07500961A (enExample) |
| AU (1) | AU660629B2 (enExample) |
| CA (1) | CA2092323A1 (enExample) |
| WO (1) | WO1992006180A1 (enExample) |
Families Citing this family (192)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5889169A (en) * | 1991-05-16 | 1999-03-30 | Cold Spring Harbor Laboratory | Cell cycle regulatory protein p16 gene |
| US7550561B1 (en) | 1991-05-16 | 2009-06-23 | Cold Spring Harbor Laboratory | p16INK4 polypeptides |
| NZ244306A (en) * | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
| US5981273A (en) * | 1991-09-30 | 1999-11-09 | Boehringer Ingelheim Int'l. Gmbh | Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells |
| US5521291A (en) * | 1991-09-30 | 1996-05-28 | Boehringer Ingelheim International, Gmbh | Conjugates for introducing nucleic acid into higher eucaryotic cells |
| SE503225C2 (sv) * | 1991-10-30 | 1996-04-22 | Leif Lindholm Konsult Ab | Virus-antikroppskomplex för införing av virus i mammalieceller |
| US5922859A (en) * | 1992-02-01 | 1999-07-13 | Boehringer Ingelheim International Gmbh | Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells |
| WO1993022433A2 (de) * | 1992-04-28 | 1993-11-11 | Frank Andreas Harald Meyer | Medikament zur gentherapeutischen behandlung von menschen, tieren und pflanzen, insbesondere zur blockierung der virenvermehrung und der tumorgene sowie verfahren zur herstellung des medikaments |
| GB9213601D0 (en) * | 1992-06-26 | 1992-08-12 | Mastico Robert A | Protein based delivery system |
| WO1994006923A1 (en) * | 1992-09-24 | 1994-03-31 | The University Of Connecticut | Modification of a virus to redirect infectivity and enhance targeted delivery of polynucleotides to cells |
| US6211334B1 (en) | 1992-10-16 | 2001-04-03 | Cold Spring Harbor | Cell-cycle regulatory proteins, and uses related thereto |
| US5962316A (en) | 1992-10-16 | 1999-10-05 | Cold Spring Harbor Laboratory | Cell-cycle regulatory proteins, and uses related thereto |
| GB9223084D0 (en) * | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
| CA2148934C (en) * | 1992-11-09 | 2005-08-02 | French W. Anderson | Targetable vector particles |
| US5869331A (en) * | 1992-11-20 | 1999-02-09 | University Of Medicine & Dentistry Of New Jersey | Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins |
| US6534051B1 (en) | 1992-11-20 | 2003-03-18 | University Of Medicine And Dentistry Of New Jersey | Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins |
| CA2149889A1 (en) * | 1992-11-20 | 1994-06-09 | Ralph C. Dornburg | Cell-type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins |
| US6043030A (en) * | 1992-12-17 | 2000-03-28 | Cold Spring Harbor Laboratory | Cell-cycle regulatory proteins, and uses related thereto |
| US6331390B1 (en) | 1992-12-17 | 2001-12-18 | Cold Spring Harbor Laboratory | Cell-cycle regulatory proteins, and uses related thereto |
| DE4311651A1 (de) * | 1993-04-08 | 1994-10-13 | Boehringer Ingelheim Int | Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen |
| US5645829A (en) * | 1993-06-18 | 1997-07-08 | Beth Israel Hospital Association | Mesothelial cell gene therapy |
| US7691632B2 (en) | 1993-11-18 | 2010-04-06 | Cold Spring Harbor Laboratory | Kit for detecting the level of cyclin-dependent kinase inhibitor P16 gene expression |
| US6057299A (en) * | 1994-01-13 | 2000-05-02 | Calydon, Inc. | Tissue-specific enhancer active in prostate |
| US5830686A (en) * | 1994-01-13 | 1998-11-03 | Calydon | Tissue-specific enhancer active in prostate |
| DE69520496T2 (de) * | 1994-05-13 | 2001-07-12 | Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville | Verfahren und zusammensetzungen als vehikel zur zielgerichtete einbringen von genen |
| US5728399A (en) * | 1994-06-29 | 1998-03-17 | University Of Conn. | Use of a bacterial component to enhance targeted delivery of polynucleotides to cells |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US6465253B1 (en) | 1994-09-08 | 2002-10-15 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
| US5837533A (en) * | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US7597886B2 (en) | 1994-11-07 | 2009-10-06 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| US6127525A (en) * | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
| US5770442A (en) | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
| US7002027B1 (en) | 1996-01-08 | 2006-02-21 | Canji, Inc. | Compositions and methods for therapeutic use |
| US6392069B2 (en) | 1996-01-08 | 2002-05-21 | Canji, Inc. | Compositions for enhancing delivery of nucleic acids to cells |
| US7888466B2 (en) | 1996-01-11 | 2011-02-15 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor HSATU68 |
| US7026116B1 (en) | 1996-04-04 | 2006-04-11 | Bio-Rad Laboratories, Inc. | Polymorphisms in the region of the human hemochromatosis gene |
| US6140305A (en) | 1996-04-04 | 2000-10-31 | Bio-Rad Laboratories, Inc. | Hereditary hemochromatosis gene products |
| US6849399B1 (en) | 1996-05-23 | 2005-02-01 | Bio-Rad Laboratories, Inc. | Methods and compositions for diagnosis and treatment of iron misregulation diseases |
| US6319504B1 (en) | 1996-06-24 | 2001-11-20 | University Of Maryland Biotechnology Institute | Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin |
| US6074850A (en) * | 1996-11-15 | 2000-06-13 | Canji, Inc. | Retinoblastoma fusion polypeptides |
| IL129922A0 (en) | 1996-11-15 | 2000-02-29 | Canji Inc | Tissue specific expression of retinoblastoma protein |
| AU737727B2 (en) | 1997-04-10 | 2001-08-30 | University Of Southern California | Modified viral surface proteins for binding to extracellular matrix components |
| US6004798A (en) * | 1997-05-14 | 1999-12-21 | University Of Southern California | Retroviral envelopes having modified hypervariable polyproline regions |
| WO1998055611A1 (en) * | 1997-06-06 | 1998-12-10 | Regents Of The University Of Michigan | Neuregulin response element and uses therefor |
| DE69838584T2 (de) | 1997-08-04 | 2008-06-26 | Cell Genesys, Inc., Foster City | Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung |
| EP2308996A1 (en) | 1998-03-30 | 2011-04-13 | NorthWest Biotherapeutics, Inc. | Therapeutic and diagnostic applications based on the role of the CXCR-4 and SDF-1 genes in tumourigenesis |
| BR9909472A (pt) | 1998-04-07 | 2001-09-11 | Corixa Corp | Polipeptìdeo purificado, processo para prevenir tuberculose, e, composição farmacêutica |
| US7078483B2 (en) | 1998-04-29 | 2006-07-18 | University Of Southern California | Retroviral vectors including modified envelope escort proteins |
| US6777388B1 (en) | 1998-08-21 | 2004-08-17 | Clf Medical Technology Acceleration Program, Inc. | Leptin-related peptides |
| DE69942837D1 (de) | 1998-11-19 | 2010-11-18 | Univ Georgetown | Systemisches virus/ligand genabgabemittel und gentherapie |
| WO2000050620A2 (en) | 1999-02-26 | 2000-08-31 | Human Genome Sciences, Inc. | Human endokine alpha and methods of use |
| GB9908195D0 (en) | 1999-04-09 | 1999-06-02 | Microbiological Res Authority | Treatment of intracellular infection |
| US7566452B1 (en) | 1999-05-04 | 2009-07-28 | New York University | Cancer treatment with endothelin receptor antagonists |
| AU5011200A (en) | 1999-05-14 | 2000-12-05 | Arbor Vita Corporation | Molecular interactions in hematopoietic cells |
| US20020064520A1 (en) * | 1999-08-19 | 2002-05-30 | Yanina Rozenberg | Targeted artificial gene delivery |
| AU784746B2 (en) | 1999-11-18 | 2006-06-08 | Dendreon Corporation | Nucleic acids encoding endotheliases, endotheliases and uses thereof |
| ATE391789T1 (de) | 1999-12-10 | 2008-04-15 | Invitrogen Corp | Verwendung einer vielzahl von rekombinationsstellen mit einzigartiger spezifität beim rekombinatorischen klonen |
| AU2002219944B2 (en) | 2000-11-28 | 2008-02-21 | Medimmune, Llc | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| US7700341B2 (en) | 2000-02-03 | 2010-04-20 | Dendreon Corporation | Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
| US7348014B2 (en) | 2000-04-14 | 2008-03-25 | Transgene, S.A. | Poxvirus with targeted infection specificity |
| CA2341356C (en) * | 2000-04-14 | 2011-10-11 | Transgene S.A. | Poxvirus with targeted infection specificity |
| EP1294949A4 (en) | 2000-06-15 | 2004-08-25 | Human Genome Sciences Inc | HUMAN TUMORNESCROSE FACTOR DELTA AND EPSILON |
| AU2001268427B2 (en) | 2000-06-16 | 2007-03-29 | Glaxosmithkline Intellectual Property Limited | Antibodies that immunospecifically bind to blys |
| EP2065052A3 (en) | 2000-08-30 | 2009-08-19 | Pfizer Products Inc. | Anti-IgE vaccines |
| JP4802401B2 (ja) * | 2000-11-07 | 2011-10-26 | トランスジェン・ソシエテ・アノニム | 標的化感染特異性を有するポックスウイルス |
| US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US7125703B2 (en) | 2001-03-13 | 2006-10-24 | Dendreon Corporation | Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon |
| US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
| US8231878B2 (en) | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| US7172892B2 (en) | 2001-03-22 | 2007-02-06 | Dendreon Corporation | Nucleic acid molecules encoding serine protease CVSP14, the encoded polypeptides and methods based thereon |
| JP2005506047A (ja) | 2001-03-27 | 2005-03-03 | デンドレオン・サンディエゴ・リミテッド・ライアビリティ・カンパニー | 膜貫通型セリンプロテアーゼ９をコード化する核酸分子、コード化されたポリペプチドおよびそれらに基づく方法 |
| WO2002079447A2 (en) | 2001-03-30 | 2002-10-10 | Avigenics, Inc. | Avian lysozyme promoter |
| US7176300B2 (en) | 2001-03-30 | 2007-02-13 | Avigenics, Inc. | Avian lysozyme promoter |
| US7541512B2 (en) | 2001-03-30 | 2009-06-02 | Synageva Biopharma Corp. | Avians containing a lysozyme promoter transgene |
| JP2004536579A (ja) | 2001-04-13 | 2004-12-09 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | 血管内皮増殖因子２ |
| FI116851B (fi) | 2001-05-03 | 2006-03-15 | Fit Biotech Oyj Plc | Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita |
| US7112430B2 (en) | 2001-05-14 | 2006-09-26 | Dendreon Corporation | Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon |
| MXPA03010747A (es) | 2001-05-25 | 2004-03-02 | Human Genome Sciences Inc | Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral. |
| WO2003002746A2 (en) | 2001-06-29 | 2003-01-09 | Novartis Ag | Perv screening method and use thereof |
| US7550650B2 (en) | 2001-09-18 | 2009-06-23 | Synageva Biopharma Corp. | Production of a transgenic avian by cytoplasmic injection |
| WO2003046176A2 (en) | 2001-11-26 | 2003-06-05 | Hybrigenics | Protein-protein interactions in human immunodeficiency virus |
| US6875588B2 (en) | 2001-11-30 | 2005-04-05 | Avigenics, Inc. | Ovomucoid promoter and methods of use |
| US7294507B2 (en) | 2001-11-30 | 2007-11-13 | Avigenics, Inc. | Ovomucoid promoters and methods of use |
| US7335761B2 (en) | 2001-11-30 | 2008-02-26 | Avigenics, Inc. | Avian gene expression controlling regions |
| US7255874B1 (en) | 2001-12-21 | 2007-08-14 | Closure Medical Corporation | Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto |
| EP2360476B1 (en) | 2002-02-13 | 2017-10-25 | BioMedica Diagnostics Inc. | Methods for selecting treatment regimens and predicting outcomes in cancer patients |
| US7135562B2 (en) | 2002-03-14 | 2006-11-14 | University Of Cincinnati | Avian iFABP gene expression controlling region |
| US20050249721A1 (en) * | 2002-04-02 | 2005-11-10 | Houston L L | Compositions and methods for targeted biological delivery of molecular carriers |
| EP2270049A3 (en) | 2002-04-12 | 2011-03-09 | Medimmune, Inc. | Recombinant anti-interleukin-9-antibody |
| PT1534335E (pt) | 2002-08-14 | 2012-02-28 | Macrogenics Inc | Anticorpos específicos de fcγriib e processos para a sua utilização |
| US7544499B2 (en) | 2002-12-16 | 2009-06-09 | Halozyme, Inc. | Human chondroitinase glycoprotein (CHASEGP), process for preparing the same, and pharmaceutical compositions comprising thereof |
| US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| AU2004206250B8 (en) | 2003-01-21 | 2009-09-17 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof |
| WO2004071462A2 (en) | 2003-02-12 | 2004-08-26 | Johns Hopkins University | Methods and compositions for treatment of viral infections based on tsg101-vps28 interaction |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| EP2330213A1 (en) | 2003-03-05 | 2011-06-08 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| KR101224235B1 (ko) | 2003-04-11 | 2013-01-25 | 메디뮨 엘엘씨 | 재조합 ｉｌ９ 항체 및 그의 용도 |
| EP2298869A1 (en) | 2003-06-13 | 2011-03-23 | University Of Medicine And Dentistry Of New Jersey | Recombinant protein production in the presence of mRNA interferase |
| CA2532250A1 (en) | 2003-07-15 | 2005-02-03 | Barros Research Institute | Compositions and methods for immunotherapy of cancer and infectious diseases |
| EP2128270B1 (en) | 2003-08-08 | 2012-10-03 | Genenews Inc. | Osteoarthritis biomarkers and uses thereof |
| EP1660186B1 (en) | 2003-08-18 | 2013-12-25 | MedImmune, LLC | Humanization of antibodies |
| WO2005032572A2 (en) | 2003-10-03 | 2005-04-14 | Vib Vzw | Means and methods for the recruitment and identification of stem cells |
| US20050227251A1 (en) | 2003-10-23 | 2005-10-13 | Robert Darnell | Method of purifying RNA binding protein-RNA complexes |
| ES2687645T3 (es) | 2003-10-27 | 2018-10-26 | Merck Sharp & Dohme Corp. | Método de diseño de ARNip para el silenciamiento de genes |
| MX361174B (es) | 2003-12-23 | 2018-11-29 | Genentech Inc | Anticuerpos anti-il13 novedosos y sus usos. |
| EP1786463A4 (en) | 2004-03-26 | 2009-05-20 | Human Genome Sciences Inc | ANTIBODY AGAINST NOGO RECEPTOR |
| WO2006001888A2 (en) | 2004-04-16 | 2006-01-05 | Acuity Pharmaceuticals Inc | Compositions and methods for inhibiting angiogenesis |
| US10066268B2 (en) | 2004-05-07 | 2018-09-04 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Methods of diagnosing or treating prostate cancer using the ERG gene, alone or in combination with other over or under expressed genes in prostate cancer |
| ES2660765T3 (es) | 2004-06-21 | 2018-03-26 | The Board Of Trustees Of The Leland Stanford Junior University | Genes y rutas expresadas de forma diferencial en trastorno bipolar y/o trastorno depresivo mayor |
| US9006181B2 (en) | 2004-07-21 | 2015-04-14 | The Administrators Of The Tulane Educational Fund | Treatment of renal dysfunction and multiple myeloma using PACAP compounds |
| US20090325150A1 (en) | 2004-07-30 | 2009-12-31 | Mount Sinai School Of Medicine Of New York University | Klf6 alternative splice forms and a germline klf6 dna polymorphism associated with increased cancer risk |
| WO2006047639A2 (en) | 2004-10-27 | 2006-05-04 | Medimmune, Inc. | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
| WO2006055635A2 (en) | 2004-11-15 | 2006-05-26 | Mount Sinai School Of Medicine Of New York University | Compositions and methods for altering wnt autocrine signaling |
| GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
| NZ556158A (en) | 2004-12-22 | 2010-04-30 | Auckland Uniservices Ltd | Trefoil factors and methods of treating proliferation disorders using same |
| BRPI0607306A2 (pt) | 2005-01-25 | 2009-08-25 | Prolexys Pharmaceuticals Inc | derivados de quinoxalina como agentes anti-tumor |
| CN103497993A (zh) | 2005-02-07 | 2014-01-08 | 基因信息公司 | 轻度骨关节炎生物标志物及其用途 |
| EP1869192B1 (en) | 2005-03-18 | 2016-01-20 | MedImmune, LLC | Framework-shuffling of antibodies |
| JP5838021B2 (ja) | 2005-04-15 | 2015-12-24 | マクロジェニクス，インコーポレーテッド | 共有結合型ダイアボディとその使用 |
| EP3782655A1 (en) | 2005-05-17 | 2021-02-24 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
| US8088382B2 (en) | 2005-07-05 | 2012-01-03 | Cornell Research Foundation, Inc. | Methods of inhibiting transendothelial migration of neutrophils and monocytes with anti-CD99L2 antibodies |
| DK2573114T3 (en) | 2005-08-10 | 2016-07-04 | Macrogenics Inc | The identification and production of antibodies with variant Fc regions, and methods of using same |
| US8249814B2 (en) | 2005-10-21 | 2012-08-21 | Genenews Inc. | Method, computer readable medium, and system for determining a probability of colorectal cancer in a test subject |
| DK2500030T4 (en) | 2005-11-04 | 2018-10-29 | Genentech Inc | Use of complement pathway inhibitors for the treatment of eye diseases |
| EP2564864B8 (en) | 2005-11-12 | 2015-05-13 | The Board of Trustees of The Leland Stanford Junior University | FGF2-related methods for diagnosing and treating depression |
| EP2387995A1 (en) | 2006-03-30 | 2011-11-23 | PTC Therapeutics, Inc. | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith |
| EP2029173B1 (en) | 2006-06-26 | 2016-07-20 | MacroGenics, Inc. | Fc riib-specific antibodies and methods of use thereof |
| US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
| EP2484696B1 (en) | 2006-08-28 | 2017-08-16 | Kyowa Hakko Kirin Co., Ltd. | Antagonistic hLIGHT-specific human monoclonal antibodies |
| AU2007324128B2 (en) | 2006-10-10 | 2013-10-10 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alterations |
| EP2064335A4 (en) | 2006-10-16 | 2011-03-30 | Medimmune Llc | MOLECULES WITH REDUCED HALF TIME, COMPOSITIONS AND ITS USE |
| EP2514439A1 (en) | 2006-11-15 | 2012-10-24 | Functional Genetics, Inc. | Anti-TSG101antibodies and their uses for treatment of viral infections |
| EP2099827B1 (en) | 2006-12-18 | 2018-11-21 | Genentech, Inc. | Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases |
| US8664364B2 (en) | 2007-01-24 | 2014-03-04 | Carnegie Mellon University | Optical biosensors |
| EP2150273A4 (en) | 2007-04-27 | 2010-11-17 | Univ Toledo | MODIFIED PLASMINOGEN ACTIVATOR INHIBITOR MOLECULE AND METHODS OF USE |
| EP2158221B1 (en) | 2007-06-21 | 2018-08-29 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| CA2691166A1 (en) | 2007-06-27 | 2008-12-31 | Liu Dongxu | Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof |
| EP2195023B1 (en) | 2007-08-29 | 2018-03-07 | Sanofi | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses |
| SG189730A1 (en) | 2008-04-02 | 2013-05-31 | Macrogenics Inc | Her2/neu-specific antibodies and methods of using same |
| CN106349390B (zh) | 2008-04-02 | 2019-12-10 | 宏观基因有限公司 | Bcr-复合体-特异性抗体和其使用方法 |
| US7928189B2 (en) | 2008-05-05 | 2011-04-19 | Ottawa Health Research Institute | PCSK9 polypeptide fragment |
| WO2010033279A2 (en) | 2008-06-04 | 2010-03-25 | Macrogenics, Inc. | Antibodies with altered binding to fcrn and methods of using same |
| WO2010027364A1 (en) | 2008-09-07 | 2010-03-11 | Glyconex Inc. | Anti-extended type i glycosphingolipid antibody, derivatives thereof and use |
| JP5734201B2 (ja) | 2008-12-19 | 2015-06-17 | マクロジェニクス，インコーポレーテッド | 共有結合型ダイアボディ及びその使用 |
| US20110312872A1 (en) | 2008-12-22 | 2011-12-22 | Universität Regensburg | Norrin in the treatment of diseases associated with an increased tgf-beta activity |
| JP2012518072A (ja) | 2009-02-18 | 2012-08-09 | カーネギー メロン ユニバーシティ | 明検出のためのクエンチャー付加デンドリマー色素 |
| US11096901B2 (en) | 2009-03-06 | 2021-08-24 | Metaqor Llc | Dynamic bio-nanoparticle platforms |
| JP5802195B2 (ja) | 2009-04-27 | 2015-10-28 | オタワ ホスピタル リサーチ インスティチュート | 幹細胞を調節するための組成物および方法ならびにその使用 |
| EP2437767B1 (en) | 2009-06-01 | 2015-07-08 | MedImmune, LLC | Molecules with extended half-lives and uses thereof |
| MX2012001882A (es) | 2009-08-13 | 2012-04-11 | Crucell Holland Bv | Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso. |
| WO2011035205A2 (en) | 2009-09-18 | 2011-03-24 | Calmune Corporation | Antibodies against candida, collections thereof and methods of use |
| CN102711772A (zh) | 2009-10-16 | 2012-10-03 | 奥克兰联合服务有限公司 | Artemin拮抗剂的抗肿瘤用途 |
| JP5908406B2 (ja) | 2009-11-02 | 2016-04-26 | ジ アドミニストレーターズ オブ ザ トゥレーン エデュケーショナル ファンド | 下垂体アデニル酸シクラーゼ活性化ポリペプチド（ｐａｃａｐ）の類似体およびその使用方法 |
| EP2496604B1 (en) | 2009-11-06 | 2017-08-23 | IDEXX Laboratories, Inc. | Canine anti-cd20 antibodies |
| WO2011088435A1 (en) | 2010-01-15 | 2011-07-21 | Cornell University | Methods for reducing protein levels in a cell |
| EP2577309B1 (en) | 2010-05-25 | 2016-11-23 | Carnegie Mellon University | Targeted probes of cellular physiology |
| EP2591000B1 (en) | 2010-07-09 | 2017-05-17 | Janssen Vaccines & Prevention B.V. | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use |
| ES2667100T3 (es) | 2010-08-02 | 2018-05-09 | Macrogenics, Inc. | Diacuerpos covalentes y sus usos |
| EP3026432A3 (en) | 2010-12-27 | 2016-07-27 | Brown University | Method for predicting patient's response to biglycan treatment |
| WO2012094511A2 (en) | 2011-01-05 | 2012-07-12 | Rhode Island Hospital | Compositions and methods for the treatment of orthopedic disease or injury |
| US9376495B2 (en) | 2011-05-21 | 2016-06-28 | Macrogenics, Inc. | Deimmunized serum-binding domains and their use in extending serum half-life |
| AU2012308476B2 (en) | 2011-09-16 | 2016-04-14 | Fate Therapeutics, Inc. | Wnt compositions and therapeutic uses of such compositions |
| EP2751257B1 (en) | 2011-09-16 | 2018-06-27 | Ottawa Hospital Research Institute | Wnt7a compositions and methods of using the same |
| RS57827B1 (sr) | 2012-02-15 | 2018-12-31 | Novo Nordisk As | Antitela koja vezuju protein 1 prepoznavanja peptidoglikana |
| JP6411218B2 (ja) | 2012-02-15 | 2018-10-24 | ノヴォ ノルディスク アー／エス | 骨髄細胞で発現されるトリガー受容体１（ｔｒｅｍ−１）に結合し、それを遮断する抗体 |
| US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| WO2014006063A2 (en) | 2012-07-02 | 2014-01-09 | Medizinische Universität Wien | Complement split product c4d for the treatment of inflammatory conditions |
| US20140120116A1 (en) | 2012-10-26 | 2014-05-01 | The Chinese University Of Hong Kong | Treatment of cancer using smad3 inhibitor |
| WO2014120975A1 (en) | 2013-02-01 | 2014-08-07 | California Institute Of Technology | Antibody-mediated immunocontraception |
| EP3450571B1 (en) | 2014-02-24 | 2023-04-05 | Celgene Corporation | Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders |
| JP6832709B2 (ja) | 2014-05-16 | 2021-02-24 | メディミューン，エルエルシー | 新生児Ｆｃ受容体結合が改変されて治療および診断特性が強化された分子 |
| US9458464B2 (en) | 2014-06-23 | 2016-10-04 | The Johns Hopkins University | Treatment of neuropathic pain |
| CN106536559B (zh) | 2014-07-17 | 2021-04-27 | 诺和诺德股份有限公司 | 定点诱变trem-1抗体以降低黏度 |
| CN107429075B (zh) | 2014-11-17 | 2022-11-01 | 卡内基梅隆大学 | 可激活的双组份光敏剂 |
| US10729790B2 (en) | 2015-05-26 | 2020-08-04 | Salk Institute For Biological Studies | Motor neuron-specific expression vectors |
| US10966414B2 (en) | 2015-05-26 | 2021-04-06 | California Institute Of Technology | Population control using engineered translocations |
| US9920100B2 (en) | 2015-06-05 | 2018-03-20 | The Chinese University Of Hong Kong | Mimotopes of tropomyosin for use in immunotherapy for shellfish and/or arthropod allergy |
| US20190145961A1 (en) | 2016-04-20 | 2019-05-16 | Washington University | Ppar agonist or lxr agonist for use in the treatment of systemic lupus erythematosus by modulation of lap activity |
| CR20250022A (es) | 2018-04-02 | 2025-02-25 | Bristol Myers Squibb Co | Anticuerpos anti-trem-1, ácidos nucleicos y vectores de los mismos (divisional 2020-0450) |
| US11965172B2 (en) | 2018-11-05 | 2024-04-23 | California Institute Of Technology | DNA sequence modification-based gene drive |
| WO2020097261A1 (en) | 2018-11-06 | 2020-05-14 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | New compositions and methods for treating beta-globinopathies |
| GB201914296D0 (en) | 2019-10-03 | 2019-11-20 | Univ Oxford Innovation Ltd | Treatment |
| US20250325469A1 (en) | 2021-01-24 | 2025-10-23 | Michael David FORREST | Inhibitors of atp synthase - cosmetic and therapeutic uses |
| IL308337A (en) | 2021-05-13 | 2024-01-01 | Us Health | Preparations and methods for the treatment of sickle cell disease |
| EP4373528A2 (en) | 2021-07-19 | 2024-05-29 | New York University | Adeno-associated viral vector compositions and methods of promoting muscle regeneration |
| US20260139028A1 (en) | 2021-11-02 | 2026-05-21 | The Regents Of The University Of California | P-selectin mutants and modulation of integrin-mediated signaling |
| UY40097A (es) | 2022-01-07 | 2023-07-14 | Johnson & Johnson Entpr Innovation Inc | Materiales y métodos de proteínas de unión a il-1b |
| US20250092106A1 (en) | 2022-01-25 | 2025-03-20 | The Regents Of The University Of California | Vegf mutants and modulation of integrin-mediated signaling |
| WO2024013727A1 (en) | 2022-07-15 | 2024-01-18 | Janssen Biotech, Inc. | Material and methods for improved bioengineered pairing of antigen-binding variable regions |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE68927996T2 (de) * | 1988-02-05 | 1997-12-04 | Hughes Howard Med Inst | Modifizierte hepatozyten und deren anwendung |
-
1991
- 1991-09-27 AU AU88603/91A patent/AU660629B2/en not_active Ceased
- 1991-09-27 CA CA 2092323 patent/CA2092323A1/en not_active Abandoned
- 1991-09-27 WO PCT/US1991/007103 patent/WO1992006180A1/en not_active Ceased
- 1991-09-27 EP EP91919436A patent/EP0553235A1/en not_active Withdrawn
- 1991-09-27 JP JP3517570A patent/JPH07500961A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO1992006180A1 (en) | 1992-04-16 |
| AU8860391A (en) | 1992-04-28 |
| EP0553235A4 (enExample) | 1994-02-09 |
| AU660629B2 (en) | 1995-07-06 |
| JPH07500961A (ja) | 1995-02-02 |
| EP0553235A1 (en) | 1993-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU660629B2 (en) | Targeting viruses and cells for selective internalization by cells | |
| Neda et al. | Chemical modification of an ecotropic murine leukemia virus results in redirection of its target cell specificity | |
| JP3934005B2 (ja) | ウイルス仲介ｄｎａ導入の増強 | |
| Straight et al. | The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes | |
| Lu et al. | Protease-induced infectivity of hepatitis B virus for a human hepatoblastoma cell line | |
| US6287857B1 (en) | Nucleic acid delivery vehicles | |
| Hobman et al. | Assembly of rubella virus structural proteins into virus-like particles in transfected cells | |
| TW520395B (en) | Methods for enhanced virus-mediated DNA transfer using molecules with virus-and cell-binding domains | |
| CA2192687C (en) | Use of a bacterial component to enhance targeted delivery of polynucleotides to cells | |
| Wang et al. | Plasma membrane receptors for ecotropic murine retroviruses require a limiting accessory factor | |
| JPH07500009A (ja) | 高等真核細胞に核酸を導入するための新規結合体 | |
| EP1549756A2 (en) | Recombinatant mutants of rhabdovirus and methods of use thereof | |
| US5843770A (en) | Antisense constructs directed against viral post-transcriptional regulatory sequences | |
| WO1994006923A1 (en) | Modification of a virus to redirect infectivity and enhance targeted delivery of polynucleotides to cells | |
| Spearman et al. | Human immunodeficiency virus type 1 capsid formation in reticulocyte lysates | |
| AU2662999A (en) | Nucleic acid delivery vehicles | |
| Rubin et al. | Receptor utilization by reovirus type 3: distinct binding sites on thymoma and fibroblast cell lines result in differential compartmentalization of virions | |
| Fujisawa et al. | Characterization of glycosylated Gag expressed by a neurovirulent murine leukemia virus: identification of differences in processing in vitro and in vivo | |
| US6503499B1 (en) | Viral vector complexes having adapters of predefined valence | |
| CN120965893B (zh) | 一种BaEV-G包膜糖蛋白、其优化方法及涉及该包膜糖蛋白的包膜质粒、包装方法和试剂盒 | |
| Bitzer et al. | Sendai virus efficiently infects cells via the asialoglycoprotein receptor and requires the presence of cleaved F0 precursor proteins for this alternative route of cell entry | |
| Sengupta et al. | Role of surface promoter mutations in hepatitis B surface antigen production and secretion in occult hepatitis B virus infection | |
| CA2189582A1 (en) | Sv-40 derived dna constructs comprising exogenous dna sequences | |
| Granowitz et al. | Substitution mutations affecting a small region of the Moloney murine leukemia virus MA gag protein block assembly and release of virion particles | |
| Poulsen et al. | Increased neurovirulence of polytropic mouse retroviruses delivered by inoculation of brain with infected neural stem cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |